Alerts will be sent to your verified email
Verify EmailJUBLPHARMA
Jubilant Pharmova
|
Caplin Point Lab
|
Eris Lifesciences
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
Australia DMF fillings
|
14.0 . | n/a | n/a |
US DMF Filings
|
98.0 . | n/a | n/a |
Canada DMF fillings
|
42.0 . | n/a | n/a |
Japan DMF Filings
|
15.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
100.0 . | 44.0 . | n/a |
Number of ANDA's Approved By USFDA
|
62.0 . | 30.0 . | n/a |
Number of ANDA's Filed in Europe
|
38.0 | n/a | n/a |
Number of ANDA's Approved in Europe
|
37.0 | n/a | n/a |
Number of ANDA's Filed in Canada
|
24.0 | n/a | n/a |
Number of ANDA's Approved by Canada
|
24.0 | n/a | n/a |
R&D as a % of Total Sales
|
0.33 % | 4.07 % | 0.0 |
Financials
|
|||
5 yr Average ROE
|
8.35 % | 20.61 % | 19.85 % |
5yr average Equity Multiplier
|
2.0 | 1.17 | 1.5 |
5yr Average Asset Turnover Ratio
|
0.59 | 0.72 | 0.58 |
5yr Avg Net Profit Margin
|
7.13 % | 24.8 % | 25.85 % |
Price to Book
|
2.94 | 7.17 | 6.59 |
P/E
|
29.46 | 36.94 | 52.44 |
5yr Avg Cash Conversion Cycle
|
-19.21 Days | 79.85 Days | -99.43 Days |
Inventory Days
|
81.78 Days | 64.55 Days | 26.22 Days |
Days Receivable
|
51.11 Days | 100.92 Days | 61.69 Days |
Days Payable
|
173.51 Days | 74.04 Days | 164.23 Days |
5yr Average Interest Coverage Ratio
|
3.98 | 579.71 | 94.87 |
5yr Avg ROCE
|
9.05 % | 25.27 % | 21.14 % |
5yr Avg Operating Profit Margin
|
18.69 % | 30.87 % | 34.25 % |
5 yr average Debt to Equity
|
0.64 | 0.01 | 0.29 |
5yr CAGR Net Profit
|
-38.8 % | 16.28 % | 5.74 % |
5yr Average Return on Assets
|
4.23 % | 17.7 % | 15.49 % |
Shareholdings
|
|||
Promoter Holding
|
50.68 % | 70.56 % | 54.87 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 18.51 % |
Change in Promoter Holding (3 Yrs)
|
0.0 | 1.53 % | 2.19 % |
Change in Mutual Fund Holding (3 Yrs)
|
2.7 % | 0.48 % | 7.46 % |
Jubilant Pharmova
|
Caplin Point Lab
|
Eris Lifesciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Capex
|
Capex
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|